Sunesis Pharmaceuticals (SNSS) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $6 at Oppenheimer, Stays Bullish
March 8, 2019 1:13 PM ESTOppenheimer analyst Hartaj Singh lowered the price target on Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) to $6.00 (from $7.00) while maintaining a Outperform rating.
With the company enrolling up to 6 evaluable patients at the first therapeutic dose level of 100mg BID, we anticipate the June... More